By using artificial intelligence, Houston Methodist researchers are able to predict hospitalization outcomes of geriatric patients with dementia on the first or second day of hospital admission.
Vaborem, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and marketing this asset, and SciClone's development and commercial presence in China Menarini will receive a total payment of up to 115 million, which includes milestone payments and tiered royalty on net sales, during the term SINGAPORE, Sept. 20, 2022 /PRNewswire/ A. Menarini Asia-Pacific Holdings Pte. Ltd., part of The Menarini Group, and SciClone Pharmaceuticals (Holdings) Limited have entered into an exclusive licensing agreement to develop and commercialize Vaborem (meropenem and vaborbactam) in the People's Republic of China (China). This initiative serves to expand options to address the public health threat of antimicrobial resistant infections, specifically carbapenem-resistant Enter
Vaborem, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in ChinaThe deal brings
Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae.